ArticleJournal of pharmacokinetics and pharmacodynamics2016
Models for the red blood cell lifespan.
Article in Journal of pharmacokinetics and pharmacodynamics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 43 citations in OpenAlex.
- Long-term efficacy and safety of peptide receptor radionuclide therapy in Japanese patients with unresectable neuroendocrine tumor: extension of the Japanese phase I and phase I/II study.Annals of nuclear medicine · 2026Trial
- A semi-mechanistic population pharmacokinetic-pharmacodynamic model to assess downstream drug-target effects on erythropoiesis.Journal of pharmacokinetics and pharmacodynamics · 2025Trial
- Sensitivity and specificity of detection methods for erythropoietin doping in cyclists.Drug testing and analysis · 2019Trial
- Response of Red Blood Cell Folate to Supplementation in Nonpregnant Women is Predictable: A Proposal for Personalized Supplementation.Molecular nutrition & food research · 2018Trial
- A minimal mathematical model of red blood cell homeostasis in anemia.PLoS computational biology · 2026Article
- In-vivo toxicokinetics of chromium in human blood and urine after intravenous injection of chromate.Archives of toxicology · 2026Article
- Analysis of red blood cell lifespan and associated influencing factors in anemic dialysis patients.Renal failure · 2025Article
- Machine learning-based models for screening of anemia and leukemia using features of complete blood count reports.Scientific reports · 2025Article
- Color-resolved third harmonic generation microscopy for single-RBC HbA1c measurement and glycemic history assessment.Science advances · 2025Article
- Reticulocyte Count and Exercise Performance in Elite Athletes: A Retrospective Study.Sports (Basel, Switzerland) · 2025Article
- CDK4/6 Inhibitors-Induced Macrocytosis Is Not Associated with Hemolysis and Does Not Impact Hemoglobin Homeostasis.Cancers · 2025Article
- Review
- The effects of marine heatwaves on a coral reef snapper: insights into aerobic and anaerobic physiology and recovery.Conservation physiology · 2024Article
- Observational
- Optimizing interpretation of survival studies of fresh and aged transfused biotin-labeled RBCs.Transfusion · 2023Article
- Estimation of the hemoglobin glycation rate constant.Scientific reports · 2021Article
- The distribution of cellular turnover in the human body.Nature medicine · 2021Article
- The Role of Feedback Control Design in Developing Anemia Management Protocols.Annals of biomedical engineering · 2021Article
- Red Blood Cell Extracellular Vesicle-Based Drug Delivery: Challenges and Opportunities.Frontiers in medicine · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
Abstract
The lifespan of red blood cells (RBCs) plays an important role in the study and interpretation of various clinical conditions. Yet, confusion about the meanings of fundamental terms related to cell survival and their quantification still exists in the literature. To address these issues, we started from a compartmental model of RBC populations based on an arbitrary full lifespan distribution, carefully defined the residual lifespan, current age, and excess lifespan of the RBC population, and then derived the distributions of these parameters. For a set of residual survival data from biotin-labeled RBCs, we fit models based on Weibull, gamma, and lognormal distributions, using nonlinear mixed effects modeling and parametric bootstrapping. From the estimated Weibull, gamma, and lognormal parameters we computed the respective population mean full lifespans (95 % confidence interval): 115.60 (109.17-121.66), 116.71 (110.81-122.51), and 116.79 (111.23-122.75) days together with the standard deviations of the full lifespans: 24.77 (20.82-28.81), 24.30 (20.53-28.33), and 24.19 (20.43-27.73). We then estimated the 95th percentiles of the lifespan distributions (a surrogate for the maximum lifespan): 153.95 (150.02-158.36), 159.51 (155.09-164.00), and 160.40 (156.00-165.58) days, the mean current ages (or the mean residual lifespans): 60.45 (58.18-62.85), 60.82 (58.77-63.33), and 57.26 (54.33-60.61) days, and the residual half-lives: 57.97 (54.96-60.90), 58.36 (55.45-61.26), and 58.40 (55.62-61.37) days, for the Weibull, gamma, and lognormal models respectively. Corresponding estimates were obtained for the individual subjects. The three models provide equally excellent goodness-of-fit, reliable estimation, and physiologically plausible values of the directly interpretable RBC survival parameters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.